Search

everythinglearnresearchcommunity

for

Search:↓

Scientists successfully created and analyzed the structure of a part of the human androgen receptor with specific modulators and a peptide to understand how it binds differently in various tissues.

The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.

Researchers developed reliable models to predict how well certain compounds bind to androgen receptors, emphasizing the importance of atomic electronegativity.

SARM-induced changes in the androgen receptor are specific to each ligand and affect stability and protein interactions.

The research found how GPCR Class A Rhodopsin receptors are related and suggested possible substances they interact with.

LPAR6 has a unique way of binding and activating, which helps in designing treatments for hair loss and cancer.

Lrig1 could be a marker for advanced sebaceous carcinoma.

Mutations in the enzyme don't significantly change how it binds to its specific substances.

The developed model can predict effective 5-alpha-reductase enzyme inhibitors.

Different ligands change the shape of the TRPV3 ion channel in unique ways.

RAGE is a potential target for melanoma treatment, but its effectiveness is uncertain due to variable expression levels.

Vitamin D receptor binds similarly to natural and synthetic ligands, affecting gene regulation.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

The research found that androgens help control blood flow in the rat prostate through a specific binding site.

Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.

LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.

LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.

New compounds show promise for treating benign prostate hyperplasia with fewer side effects.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Strontium ranelate helps cartilage growth by blocking a specific cell pathway.

A new mutation in the human glucocorticoid receptor reduces its function and causes resistance to glucocorticoids.

Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.

Analog 23 is a promising compound for prostate cancer treatment.

LTBP1 is a key regulator in diseases and a potential target for new treatments.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

LGR5 mainly stays inside cells, moving to the trans-Golgi network, and this process is important for its role in cell signaling.

Lysophospholipids can act as anti-inflammatory agents through specific receptors, but more research is needed.

R-spondins and their receptors help increase bone growth and may be used to treat bone loss diseases.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.